XOMA Royalty shareholders approve incentive plan amendments and bylaw changes

XOMA shareholders approved an expanded long-term incentive plan, a new employee stock purchase plan, bylaw changes, and the reelection of all director nominees at the 2026 annual meeting. The company also reported Q4 2025 EPS of $0.26 versus -$0.11 expected and revenue of $13.76 million versus $11.13 million consensus. Separately, Ligand Pharmaceuticals agreed to acquire XOMA for $39.00 per share in cash, valuing the deal at about $739 million and including a contingent value right tied to litigation proceeds.

Analysis

The market is effectively pricing XOMA as a clean cash deal, but the governance actions matter because they reduce the odds of process friction during the closing window. Expanding equity comp and adopting an ESPP are not economically meaningful in isolation; the real signal is that management is aligning the internal capital structure and employee incentives to avoid any operational drift while the transaction hangs over the name. In practice, that lowers the probability of talent leakage and last-mile execution issues, which is where small-cap M&A deals often leak value.

The bigger second-order effect is on arbitrage quality. With the stock already near deal value, upside from here is mostly a function of litigation/CVR optionality rather than spread compression, so the position behaves more like a binary event trade than a standard merger arb. That means realized carry is poor and the main risk is not headline spread widening, but a longer-than-expected closing process that ties up capital while downside is capped but not eliminated.

LGND is the cleaner expression of the strategic thesis if you believe the acquisition is accretive and the litigation CVR is over-discounted. The market may be underestimating how much deal certainty and platform consolidation matter in specialty pharma: acquisition of royalty streams is a scale game, and the winner is the buyer that can finance, underwrite, and litigate optionality more efficiently than peers. If the pending litigation monetizes, the CVR could make the headline purchase price look richer ex post, which is why the market may be too complacent about tail value transfer.

Contrarian view: the consensus is treating the transaction as fully de-risked, but the true risk is that the CVR becomes a political/legal distraction that elongates integration and creates headline overhang for LGND for months. That would not necessarily break the deal, but it could compress LGND’s multiple if investors decide the acquisition mix shifts toward uncertain contingent value rather than predictable royalty cash flows.

Key Decisions for Investors

• Maintain only a small XOMA merger-arb stub, with a 1-3 month horizon; the expected return from spread capture is limited, so size should reflect headline-risk asymmetry rather than deal certainty.
• Prefer LGND long exposure on pullbacks versus chasing XOMA at the deal price; if the market is underpricing post-close accretion and litigation optionality, LGND offers the better risk/reward over a 3-6 month horizon.
• Avoid initiating fresh XOMA longs here unless you are specifically underwriting the CVR; at current levels the trade is largely a capped-upside, delayed-settlement instrument with poor convexity.
• If you want event-driven optionality, consider LGND call spreads out 4-6 months to express upside from post-announcement rerating while limiting downside if the CVR proves noisy.
• Watch for any delay in regulatory or shareholder process; if closing slips by more than 30-45 days, the XOMA spread can widen meaningfully while LGND may see a short-term de-rating.